Skip to main content

Breast Cancer Research and Treatment

Ausgabe 3/2022

Inhalt (21 Artikel)

miRNAs as therapeutic predictors and prognostic biomarkers of neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis

  • Review

Zhuo Zhang, Hanxu Zhang, Jiao Yu, Ling Xu, Xiaocong Pang, Qian Xiang, Qianxin Liu, Yimin Cui

Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer

  • Preclinical study

Lili Chen, Yanyang Chen, Zhongpeng Xie, Jiao Luo, Yuefeng Wang, Jianwen Zhou, Leilei Huang, Hongxia Li, Linhai Wang, Pei Liu, Man Shu, Wenhui Zhang, Zunfu Ke

Tumor-associated mononuclear cells in the tumor bed of triple-negative breast cancer associate with clinical outcomes in the post-neoadjuvant chemotherapy setting

  • Clinical trial

Thaer Khoury, Saif Aljabab, Song Yao, Christine Ambrosone, Angela Omilian, Kristopher Attwood, Wenyan Ji, Shipra Gandhi

Awareness of link between obesity and breast cancer risk is associated with willingness to participate in weight loss intervention

  • Clinical trial

Laura Burkbauer, Macy Goldbach, Cassie Huang, Julia Lewandowski, Robert Krouse, Kelly Allison, Julia Tchou

Co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxel

  • Clinical trial

Ciao-Sin Chen, Ellen M. Lavoie Smith, Kathleen A. Stringer, N. Lynn Henry, Daniel L. Hertz

Risk of secondary malignancy after radiotherapy for breast cancer: long-term follow-up of Japanese patients with breast cancer

  • Open Access
  • Clinical trial

Noriyuki Okonogi, Kumiko Karasawa, Yuki Nitta, Yasumasa Mori, Kazutoshi Murata, Masaru Wakatsuki, Hiroshi Tsuji

Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer

  • Clinical trial

Neelima Vidula, Christina Yau, Hope Rugo

The implementation of a noninvasive lymph node staging (NILS) preoperative prediction model is cost effective in primary breast cancer

  • Open Access
  • Clinical trial

Ida Skarping, Kristoffer Nilsson, Looket Dihge, Adam Fridhammar, Mattias Ohlsson, Linnea Huss, Pär-Ola Bendahl, Katarina Steen Carlsson, Lisa Rydén

Clinical utility of MRI in the neoadjuvant management of early-stage breast cancer

  • Epidemiology

L. Corke, L. Luzhna, K. Willemsma, C. Illmann, M. Mcdermott, C. Wilson, C. Simmons, N. LeVasseur

Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis

  • Epidemiology

Tal Sella, Pedro Exman, Siyang Ren, Taylor S. Freret, Katherine E. Economy, Wendy Y. Chen, Heather A. Parsons, Nancy U. Lin, Beverly Moy, Nadine M. Tung, Ann H. Partridge, Nabihah Tayob, Erica L. Mayer

Decision quality and regret with treatment decisions in women with breast cancer: Pre-operative breast MRI and breast density

  • Epidemiology

Karen J. Wernli, Rebecca E. Smith, Louise M. Henderson, Wenyan Zhao, Danielle D. Durham, Karen Schifferdecker, Celia Kaplan, Diana S. M. Buist, Karla Kerlikowske, Diana L. Miglioretti, Tracy Onega, Nila H. Alsheik, Brian L. Sprague, Gloria Jackson-Nefertiti, Jill Budesky, Dianne Johnson, Anna N. A. Tosteson

Added value of repeat sentinel lymph node biopsy in FDG-PET/CT node-negative patients with ipsilateral breast cancer recurrence

  • Epidemiology

R. Haarsma, A. A. van Loevezijn, M. L. Donswijk, A. N. Scholten, M. T. F. D. Vrancken Peeters, F. H. van Duijnhoven

Long-term survival in elderly women receiving chemotherapy for non-metastatic breast cancer: a population-based analysis

  • Epidemiology

Matthew Castelo, Justin Lu, Lawrence Paszat, Zachary Veitch, Kuan Liu, Adena S. Scheer

Racial and ethnic disparities in the refusal of surgical treatment in women 40 years and older with breast cancer in the USA between 2010 and 2017

  • Open Access
  • Epidemiology

Pierre Fwelo, Zenab I. Yusuf, Abigail Adjei, Gabriel Huynh, Xianglin L. Du

The prevalence and predictors of adjuvant chemotherapy use among patients treated with neoadjuvant endocrine therapy

  • Epidemiology

Tal Sella, Olga Kantor, Anna Weiss, Ann H. Partridge, Otto Metzger, Tari A. King

Adherence to the 2020 American Cancer Society Guideline for Cancer Prevention and risk of breast cancer for women at increased familial and genetic risk in the Breast Cancer Family Registry: an evaluation of the weight, physical activity, and alcohol consumption recommendations

  • Epidemiology

Ashley M. Geczik, Jennifer S. Ferris, Mary Beth Terry, Irene L. Andrulis, Saundra S. Buys, Mary B. Daly, John L. Hopper, Esther M. John, Allison W. Kurian, Melissa C. Southey, Yuyan Liao, Jeanine M. Genkinger

Surgical margin status and survival outcomes of breast cancer patients treated with breast-conserving surgery and whole-breast irradiation after neoadjuvant chemotherapy

  • Original Article

Jong-Ho Cheun, Young Joo Lee, Jun-Hee Lee, Yungil Shin, Jung Whan Chun, Soo Yeon Baek, Hong-Kyu Kim, Han-Byoel Lee, Jonghan Yu, Byung Joo Chae, Wonshik Han, Jeong Eon Lee

Surveillance mammography after treatment for male breast cancer

  • Brief Communication

Siddhartha Yadav, Lindsey Sangaralingham, Stephanie R. Payne, Karthik V. Giridhar, Tina J. Hieken, Judy C. Boughey, Robert W. Mutter, John R. Hawse, Rafael E. Jimenez, Rachel A. Freedman, Sadia Khanani, Fergus J. Couch, Celine Vachon, Nilay Shah, Roberto A. Leon-Ferre, Kathryn J. Ruddy

Comment on “Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta‑analysis”

  • Letter to the Editor

Francesca Poggio, Marcello Ceppi, Piero Fregatti, Matteo Lambertini, Marco Tagliamento

Neu im Fachgebiet Onkologie

Fünf Faktoren sagen Lymphödeme nach Brustkrebs voraus

Ob nach der operativen Behandlung von Brustkrebs ein Lymphödem droht, lässt sich anhand eines Risikomodells abschätzen, das auf fünf leicht verfügbaren klinischen Parametern beruht.

Genügt die biparametrische MRT für die Prostatadiagnostik?

Die multiparametrische Magnetresonanztomografie hat einen festen Platz im Screening auf klinisch signifikante Prostatakarzinome. Ob auch ein biparametrisches Vorgehen ausreicht, ist in einer Metaanalyse untersucht worden.

Metastasiertes CRC: besser Checkpointhemmer im Doppelpack!

Die Kombination von Nivolumab plus Ipilimumab ist beim metastasierten Kolorektalkarzinom mit MSI-H- oder dMMR klar im Vorteil gegenüber einer Nivolumab-Monotherapie: Das Progressionsrisiko war damit in einer Phase-3-Studie um 38% reduziert.

Große Trinkmengen bei Blasentumoren möglicherweise von Nachteil

Beim nicht-muskelinvasiven Blasenkrebs scheint eine hohe Flüssigkeitszufuhr keinen schützenden Effekt in Bezug auf das Risiko eines Rezidivs oder einer Krankheitsprogression zu haben. Eine niederländische Studie legt sogar nahe, dass große Trinkmengen das Fortschreiten der Erkrankung begünstigen könnten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.